# Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults

> **NCT06033612** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 50 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** RV299
- **DRUG:** Placebo
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT06033612
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-12
- **Primary completion:** 2022-07-27
- **Final completion:** 2022-07-27
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06033612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06033612, "Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06033612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*